National Rural Utilities Cooperative Finance Corp
Change company Symbol lookup
Select an option...
NRUC National Rural Utilities Cooperative Finance Corp
UPS United Parcel Service Inc
BOLT Bolt Biotherapeutics Inc
EIX Edison International
EM Smart Share Global Ltd
WTW Willis Towers Watson PLC
DSU BlackRock Debt Strategies Fund Inc
TRTN-A Triton International Ltd
RNG RingCentral Inc
WFCF Where Food Comes From Inc
Go

Closing Price
$26.28
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
26.81
Day's Low
26.24
Volume
(Light)
Volume:
10,461

10-day average volume:
14,269
10,461

Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

10:00 am ET December 3, 2021 (PR Newswire) Print

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event - Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam's RNAi Platform Collaboration Update - at 2:00 p.m. ET on Monday, December 6, 2021.

Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center, will participate on behalf of Regeneron.

The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite(R) technologies, such as VelocImmune(R), which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:Investor Relations Mark Hudson 914.847.3482 mark.hudson@regeneron.com

https://c212.net/c/img/favicon.png?sn=NY96064&sd=2021-12-03

View original content:https://www.prnewswire.com/news-releases/regeneron-to-participate-in-hc-wainwright--co-virtual-event-301437162.html

SOURCE Regeneron Pharmaceuticals, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=NY96064&Transmission_Id=202112031000PR_NEWS_USPR_____NY96064&DateId=20211203

comtex tracking

COMTEX_398235726/1005/2021-12-03T10:00:14

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.